Have questions about our groundbreaking cancer therapies or partnership opportunities? Reach out to Theranib Inc. and join us in advancing cancer care worldwide.
Theranib at OBIO Investment Summit 2026
Thrilled to share that Theranib has been invited to pitch at OBIO in Toronto (Feb 3–6) 🇨🇦It’s an exciting opportunity to present our vision and progress to a community that’s sha
Theranib at BIOTECanada Coast to Coast Competition
Theranib secured a coveted spot to pitch at the BIOTECanada Coast to Coast Competition at BIO 2025 in Boston.This is an incredible opportunity to showcase our innovation on an international
Theranib at BIO 2025
Theranib will be attending the BIO International Convention, that is the premier global event for biotechnology and life sciences. Our team will be actively engaging with peers to explore sc
Theranib’s US Patent Published
Theranib Inc. announces the publication of its US patent on January 9, 2025, securing protection for VE3, a groundbreaking ALDH1A3-targeted cancer therapy.
Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs
Explore the pivotal role of ALDH1A3 in breast cancer progression highlighted in a recent study, reinforcing Theranib’s mission to advance ALDH1A3-targeted therapies.
ALDH1A3 and Breast Cancer Progression
Explore the pivotal role of ALDH1A3 in breast cancer progression highlighted in a recent study, reinforcing Theranib’s mission to advance ALDH1A3-targeted therapies.
The Expanding Role of ALDH1A3 in Cancer
Discover the expanding role of ALDH1A3 in cancer stem cells and its therapeutic potential, reinforcing Theranib’s focus on precision-targeted cancer therapies.